| HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma (NCT05290116) | Yunfei Yuan | 2022-07-21 |
| Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer (NCT05239169) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2022-05-23 |
| Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements (NCT05174650) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2022-04-20 |
| A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations (NCT05242822) | Kinnate Biopharma | 2022-03-29 |
| Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors (NCT05220722) | TriSalus Life Sciences, Inc. | 2022-03-02 |
| TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma (NCT05247996) | The Central Hospital of Lishui City | 2022-03-01 |
| A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC (NCT05236699) | Tongji Hospital | 2022-02-01 |
| Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma (NCT05251662) | Tianjin Medical University Cancer Institute and Hospital | 2022-01-13 |
| Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer (NCT05292443) | Geneplus-Beijing Co. Ltd. | 2021-12-20 |
| Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment (NCT05328167) | Thomas Jefferson University | 2021-12-14 |
| Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer (NCT05009953) | CSPC Ouyi Pharmaceutical Co., Ltd. | 2021-09-01 |
| GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC (NCT05019677) | Fudan University | 2021-09-01 |
| Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer (NCT05010681) | Fudan University | 2021-08-24 |
| Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma (NCT05010668) | Fudan University | 2021-08-24 |
| TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma (NCT04954781) | Fudan University | 2021-07-14 |
| HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC (NCT04961970) | Shi Ming | 2021-07-09 |
| Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma (NCT04961788) | Shanghai Zhongshan Hospital | 2021-07-01 |
| Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery (NCT04891289) | Memorial Sloan Kettering Cancer Center | 2021-05-07 |
| Infusion System for Hepatic Cancer (NCT04684862) | Ronald DeMatteo, M.D. | 2021-02-08 |
| A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea (NCT04546828) | Samsung Medical Center | 2021-02-01 |
| Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors (NCT04669496) | Shanghai Zhongshan Hospital | 2021-01-20 |
| Hepatic Artery Infusion (HAI) Program at Duke University (NCT04511793) | Michael Lidsky, M.D. | 2020-12-11 |
| Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma (NCT05327907) | Qilu Hospital of Shandong University | 2020-11-22 |
| REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors (NCT04526106) | Elevar Therapeutics | 2020-09-02 |
| A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma (NCT04479904) | Jiangsu HengRui Medicine Co., Ltd. | 2020-08-10 |
| PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery (NCT04295317) | Shanghai Zhongshan Hospital | 2020-08-01 |
| Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study (NCT04454905) | Sun Yat-sen University | 2020-08-01 |
| Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer (NCT04561453) | University of Washington | 2020-07-08 |
| Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma (NCT04299581) | Fudan University | 2020-07-07 |
| Liver Transplantation for Non-Resectable Intrahepatic Cholangiocarcinoma: a Prospective Exploratory Trial (TESLA Trial) (NCT04556214) | Oslo University Hospital | 2020-06-01 |
| Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma (NCT04078230) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2020-01-01 |
| Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) (NCT04238637) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2019-11-01 |
| A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (NCT03849469) | Xencor, Inc. | 2019-05-29 |
| Routine Lymphadenectomy for Intrahepatic Cholangiocarcinoma (NCT03796819) | First Affiliated Hospital Xi'an Jiaotong University | 2019-01-10 |
| Lenvatinib Plus PD-1 Antibody for Unresectable ICC (NCT03779100) | Shi Ming | 2018-12-17 |
| A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations (NCT03781934) | Medivir | 2018-09-05 |
| Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma (NCT03801499) | Sun Yat-sen University | 2018-09-01 |
| HAIC Versus Systemic Chemotherapy for Unresectable ICC (NCT03771846) | Shi Ming | 2018-08-01 |
| Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma (NCT03633773) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2018-07-01 |
| Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma (NCT03086993) | Delcath Systems Inc. | 2018-04-10 |
| Liver Transplantation for Early Intrahepatic Cholangiocarcinoma (NCT02878473) | University Health Network, Toronto | 2018-04-05 |
| A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma (NCT03521219) | The First Affiliated Hospital of Zhengzhou University | 2018-02-07 |
| Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (NCT03230318) | Basilea Pharmaceutica | 2017-09-28 |
| HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma (NCT05489692) | Sun Yat-sen University | 2017-09-01 |
| A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma (NCT03081039) | University of Louisville | 2017-08-21 |
| A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma (NCT03251443) | Peking Union Medical College Hospital | 2017-08-08 |
| SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma (NCT02807181) | Sirtex Medical | 2017-02-14 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (NCT02834013) | National Cancer Institute (NCI) | 2017-01-30 |
| Bortezomib in Intrahepatic Cholangiocellular Carcinoma (NCT03345303) | Zhengang Yuan | 2017-01-01 |
| Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery (NCT02881554) | University of Washington | 2016-12-21 |
| Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples (NCT02762721) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2016-06-06 |
| Treat Primary and Metastatic Liver Tumors (NCT05240040) | Methodist Health System | 2016-04-26 |
| TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection (NCT02588755) | Eastern Hepatobiliary Surgery Hospital | 2015-12-01 |
| Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma (NCT02512692) | Medical University of South Carolina | 2015-07-21 |
| Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation (NCT02273739) | Celgene | 2014-12-08 |
| Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC (NCT02254681) | Allina Health System | 2014-09-01 |
| Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer (NCT02238613) | 307 Hospital of PLA | 2014-08-01 |
| Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma (NCT02415036) | Delcath Systems Inc. | 2014-06-01 |
| Next Generation Sequencing in Intrahepatic Cholangiocarcinoma (NCT02184871) | University of Bologna | 2014-05-01 |
| Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma (NCT01938729) | Memorial Sloan Kettering Cancer Center | 2013-09-05 |
| Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma (NCT01954745) | Massachusetts General Hospital | 2013-09-01 |
| Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC) (NCT01862315) | Memorial Sloan Kettering Cancer Center | 2013-05-01 |
| Role of Bile Duct Resection in Major Hepatectomy Due to Intrahepatic Cholangiocarcinoma (NCT01862276) | Kansai Hepatobiliary Oncology Group | 2013-03-01 |
| VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway (NCT01917370) | First Affiliated Hospital, Sun Yat-Sen University | 2012-10-01 |
| Response of Hepatic Tumors to Radioembolization (NCT01775280) | University of Zurich | 2012-10-01 |
| Prognosis of Resection and Radiotherapy in the Treatment of Intrahepatic Cholangiocarcinoma Patients (NCT01914289) | Eastern Hepatobiliary Surgery Hospital | 2011-01-01 |
| Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma (NCT01668134) | Washington University School of Medicine | 2009-12-16 |
| Stereotactic Body Radiotherapy for Liver Tumors (NCT01347333) | Mercy Research | 2008-09-01 |
| Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations (NCT04087876) | Basilea Pharmaceutica | |